<DOC>
	<DOCNO>NCT00653003</DOCNO>
	<brief_summary>To compare single-dose Bioavailability Kali Aventis</brief_summary>
	<brief_title>Bioavailability Study Leflunomide Tablets Under Fed Conditions</brief_title>
	<detailed_description>To compare relative Bioavailability leflunomide 20mg tablet ARAVA 20mg tablet healthy female subject feed condition</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Malnutrition</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<criteria>Subjects meet follow criterion within 30 day prior first drug administration ( except inclusion # 8 ) Healthy , surgically sterile ( hysterectomy , bilateral oophorectomy ) postmenopausal ( al least 1 year ) female subject , 18 65 year age ( inclusive ) Indicate nonchild bearing status one follow criterion : Indication successful hysterectomy . No spontaneous menses al least 1 year , must luteinizing hormone ( LH ) follicle stimulate hormone ( FSH ) level within postmenopausal range . Indication successful bilateral oophorectomy . Body weight within 20 % appropriate weight subject 's height frame ( publish 1983 Metropolitan Life Insurance Company Scale , Statistical Bureau ) Negative : HIV Hepatitis B surface antigen Hepatitis C antibody Urine test drug abuse ( marijuana , amphetamine , barbiturate , cocaine , opiates , benzodiazepine methadone ) . Serum HCG consistent pregnancy . No significant disease clinically significant finding physical examination . No clinically significant finding vital sign measurement 12lead electrocardiogram ( ECG ) Subjects receive leflunomide within 4 month must A771726 ( Metabolite ) level 0.01ug/ml subsequent administration leflunomide since test . Note : The 30 day screen limit apply inclusion criterion . Be informed nature study give write consent prior receive study procedure . Subject fulfil follow criterion exclude study . Known history presence clinically significant medical condition . Known suspected carcinoma . Known history presence : Hypersensitivity idiosyncratic reaction leflunomide and/or drug substance similar activity . Alcoholism within last 12 month . Drug dependence and/ substance abuse . On special diet within 4 week prior drug administration ( e.g . liquid , protein , raw food diet ) . Participated another clinical trail receive investigational product 30 day prior drug administration . Donated 250 ml blood past 45 day OR donate 250 ml 500 ml past 45 day OR donate 501 ml blood past 56 day ( base Canadian Blood Services guideline blood donation ) . Requirement medication ( prescription and/ overthecounter ) routine basis , exception hormonal replacement therapy , nutritional supplement and/or occasional use common analgesic . Difficulty fast consume standard meal .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Bioequivalence , Leflunomide , feed</keyword>
</DOC>